Source comparison
PT-141 for Low Sex Drive Women Research: Comparison Table
The following table compares bremelanotide (PT-141) to the other FDA-approved treatment for female sexual dysfunction and common off-label alternatives. Bremelanotide (Vyleesi) MC4R agonist. Central dopamine/norepinephrine modulation Premenopausal HSDD 1.75mg
This comparison does not assign a generated winner or score.
- The following table compares bremelanotide (PT-141) to the other FDA-approved treatment for female sexual dysfunction and common off-label alternatives.
- Bremelanotide (Vyleesi)
- MC4R agonist. Central dopamine/norepinephrine modulation
- Premenopausal HSDD
- 1.75mg subcutaneous injection 45 min before activity, max 8 doses/month
- Nausea 40%, flushing 20%, transient BP elevation 2–3 mmHg systolic
- On-demand option with central mechanism; high nausea rate limits tolerability for many users
- Flibanserin (Addyi)
- 5-HT1A agonist / 5-HT2A antagonist. Serotonin rebalancing
- 100mg oral daily at bedtime
- Dizziness 11%, somnolence 11%, contraindicated with alcohol
- Daily dosing required; modest efficacy (0.3–0.5 FSFI point increase); alcohol restriction reduces real-world adherence
- Testosterone (off-label)
- Androgen receptor activation. Increases libido via multiple pathways
- Postmenopausal women (primary evidence base)
- Transdermal 300mcg daily (compounded) or pellet implant
- Acne, hirsutism, voice deepening (dose-dependent), lipid changes
- Not FDA-approved for sexual dysfunction; evidence strongest in surgically menopausal women; safety data limited beyond 24 months
- Buspirone (off-label)
- 5-HT1A partial agonist, dopamine D2 modulator
- Anxiety (FDA indication); SSRI-induced sexual dysfunction (off-label)
- 5–10mg 1–2 hours before activity
- Dizziness, headache; generally well-tolerated
- Limited controlled trial data for HSDD; used primarily for SSRI-related anorgasmia rather than low desire